AKESOgen, Inc. Selected as a 2018 Atlanta Metro Export Challenge Winner

orbatl_icon

AKESOgen, Inc. Selected as a 2018 Atlanta Metro Export Challenge Winner

AKESOgen, Inc. Receives $5,000 Grant to Grow Internationally

ATLANTA – November 6th, 2018 AKESOgen, Inc. is a recipient of a $5,000 grant in the annual Atlanta Metro Export Challenge (Atlanta MEC), a grant program designed to engage small- and medium-sized businesses in metro Atlanta in the development of international sales plans.

Companies from all over the 29-county region, ranging in size from pre-revenue startups to small and established medium-sized businesses, applied to the program. Thirty companies were selected in the competition and will each receive a grant of $5,000 to apply towards the growth of their international business.

“AKESOgen is honored to be a winner of the Atlanta Metro Export Challenge. This grant will help AKESOgen expand its services internationally as a global forward thinking company.”

AKESOgen offers a wide array of genomic services that include next generation sequencing, microarray processing, DNA and RNA extractions for a variety of industries such as consumer genomics, biotech, pharma, academia, and forensics.

To see the full list of grant awardees, click here

The Atlanta MEC is one of many ways to engage small- and medium-sized companies in metro Atlanta in the development of their international business. Over the last two years, the program has given out more than $400,000 to metro Atlanta companies thanks to the generous sponsorship of JPMorgan Chase & Co, which again contributed $100,000 to this year’s program. Additional sponsorship came from the Metro Atlanta Chamber, UPS, Johnson Controls and Partnership Gwinnett.

“JPMorgan Chase is pleased to help metro Atlanta businesses grow in the international economy,” said David Balos, head of JPMorgan Chase’s Middle Market Banking group in Georgia. ‘’These grants will help companies spend time in their target markets to meet with distributors, partners, and potential customers. Seeing metro Atlanta companies grow their international business will consequently lead to job creation and growth of the metro Atlanta economy.”

The Atlanta MEC is being implemented by ORBATL, a regional partnership of metro Atlanta public and private leaders that enables businesses to grow in the global economy through trade and foreign direct investment.

About AKESOgen
AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

###

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

AKESOgen, Genetic Direction partner on Nutrisystem’s launch of Groundbreaking DNA Body Blueprint™ Nationwide

All New DNA Body Blueprint Provides Integrated Personal Action Plan Focusing on Genetic-Based Eating Behaviors, Nutrition and Metabolism

Simple, Effective and Secure At-Home DNA Test is Supported by Science and Comprehensively Developed to Help Weight Loss and Weight Management

Nutrisystem DNA Body Blueprint Logo

FORT WASHINGTON, Pa.-Nutrisystem, Inc. (Nasdaq: NTRI), a leading provider of health and wellness and weight management products and services including Nutrisystem® and South Beach Diet® brands, today announced the launch of DNA Body Blueprint™, a genetic-based product using a proprietary algorithm that provides an integrated personal action plan focused on eating behaviors, nutrition and metabolism. The national marketing campaign will debut this week.

“By providing a personalized overview that is the ultimate roadmap for an individual’s ongoing nutritional needs, this product delivers on our mission of helping consumers make more informed choices and achieve outcomes that drive overall health,” commented Dawn Zier, President and CEO, Nutrisystem, Inc. “This groundbreaking use of DNA technology is a major step forward in the areas of weight loss, maintenance, and personalized nutrition. Consumer interest is high and we believe this product will attract new consumers to our brand as well as allow us to extend our relationship with them as they transition from weight loss to an ongoing healthy lifestyle.”

Years of Development Leads to National Debut

As a leader with a history in innovative and scientifically-backed weight loss solutions, Nutrisystem greenlighted the creation of DNA Body Blueprint based on a thorough assessment of market dynamics and scientific reviews from its Science Advisory Board. The board consists of a team of renowned professionals, each with distinct backgrounds and expertise, who helped evaluate existing research to enhance current programs, as well as develop new programs utilizing the latest science and technology trends within weight management.

Nutrisystem DNA Body Blueprint
The Company worked closely with and entered into an exclusive agreement with Genetic Direction, a leading provider of DNA-based health management programs, to develop a simple and secure DNA test that uses advanced genetic testing technology and genomic analysis to create an innovative and comprehensive product in the weight loss and weight management space. Proprietary algorithms were designed to accurately analyze genetic variants known as single nucleotide polymorphisms (SNPs) that may affect absorption and uptake of nutrients, processing of nutrients, metabolism, behaviors and optimal fitness approaches. For example, customers will discover whether they are more genetically inclined to lose weight and maintain weight loss, whether they have a slower or faster metabolism, and how their body processes macronutrients such as carbohydrates, fats and proteins, and what to do about it. Customers will be able to discuss their personalized report with a weight loss counselor and tailor their program based on the report findings.

“Nutrisystem, along with our Science Advisory Board, has had an eye on this space over the last few years and is pleased to see the technology safely and constructively evolve,” said David Burton, Executive Vice President of Operations at Nutrisystem, Inc. “Our mission is to match the most cutting-edge scientific developments with proven nutritional data to give our customers the best weight management experience possible, and we’re pleased to bring this to market after having worked extensively on this initiative for the last 24 months. We did an exhaustive search for the right partners and are proud to be rolling out a high-caliber offering at scale with unprecedented personalization.”

Dr. Tim Church, Medical Director, Genetic Direction, a distinguished researcher and specialist in public health and general preventive medicine and one of the country’s leading physicians in exercise and obesity research, echoed this sentiment, saying, “We’ve worked for many years to refine the science behind DNA testing as it relates to health and wellness. We now have a product that can make a difference in peoples’ lives and by working with Nutrisystem, together we can raise broad awareness and prompt mainstream adoption.”

Nutrisystem, through Genetic Direction, will be utilizing AKESOgen, an industry leading global genetic testing lab, to provide data and results using the most secure data encryption technology available, including de-identified samples and barcode matching.

Dr. Mark Bouzyk, Chief Scientific Officer, AKESOgen, who has been a global scientific leader in the precision genetics space over the last two decades commented, “The time is right to leverage the most robust and exciting scientific discoveries over the last several years in the public health and wellness continuum to benefit the community at large. This comes at a time of unprecedented cost benefits in genetic technologies that is coincidentally timely for the consumer market. Coupling this with Nutrisystem’s vision is absolutely a win-win for all.”

National Advertising & Marketing Campaign

DNA Body Blueprint is slated to be prominently featured in national multi-media marketing and advertising campaigns debuting today, July 16.

“We are thrilled to introduce our DNA-informed product nationwide, via television, social, paid digital, and eCRM. Our DNA Body Blueprint leverages what Nutrisystem does better than anyone. We start with cutting edge science, then make it simple and easy to understand. We’re excited to provide each customer with a blueprint to lose weight successfully. It’s the healthy eating approach designed by your body,” explained Keira Krausz, CMO, Nutrisystem, Inc. “We worked closely with potential customers to develop both the product and our campaign, and we know their ongoing insights will play a pivotal role in how we continue to evolve the offering.”

View one of the Body Blueprint DNA national television ads here.

White Paper & Fact Sheet

The Science Behind Nutrisystem® DNA Body Blueprint™ White Paper can be found here.
Authors: LeeAnn Kindness, MS, Mandi Knowles, RDN/LDN, Courtney McCormick, MPH, RDN/LDN, Noah Voreades, MS, Mark Bouzyk, PhD, Dr. Mark Sarzynski
Reviewers: Gary Bennett, PhD., Ted Kyle, RPh, MBA

Additional information on the Nutrisystem DNA Body Blueprint can be found here along with a fact sheet, here.

About Nutrisystem, Inc.

Nutrisystem, Inc. (Nasdaq: NTRI) is a leader in the weight-loss industry, having helped millions of people lose weight over the course of more than 45 years. The Company’s multi-brand approach to weight loss includes multiple plans for 2018. For more information, go to NutrisystemNews.com and Newsroom.SouthBeachDiet.com.

About Genetic Direction

Genetic Direction is a healthcare software company that improves individuals’ lives by evaluating key genetic markers and developing personalized health management programs in the areas of weight management, healthy aging and peak athletic performance. Genetic Direction’s proprietary algorithms and protocols utilize the latest peer-reviewed genetic research and are delivered to consumers, clients and patients through healthcare providers, retail marketing partners and directly via its secure web platform and one-on-one telehealth consultations.

About AKESOgen

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

Contacts

Nutrisystem, Inc.
Robin McConnell Shallow
Senior Vice President, Corporate Communications and Public Relations
215-346-8068
rshallow@nutrisystem.com
or
ICR, Inc.
John Mills, Partner
646-277-1254
ir@nutrisystem.com
John.Mills@Icrinc.com

AKESOgen, Inc.
Mark Bouzyk, Ph.D.
Chief Scientific Officer
770 542 0890
mbouzyk@akesogen.com
www.akesogen.com

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Disease Risk to Include Saliva Samples

Cytox Ltd

 

Cytox in Collaboration with AKESOgen Extends Genetic Test for Assessing Alzheimer’s Disease Risk to Include Saliva Samples


Pioneering polygenic risk scoring approach verified for banked DNA, blood and saliva samples

 

8th May 2018: Oxford & Manchester, UK and Atlanta, GA.  Cytox, a precision medicine testing company which today is commercializing polygenic risk scoring (PRS) and other approaches for assessing genetic risk for developing Alzheimer’s disease, has collaborated with integrated genomics and genetics leader AKESOgen to verify the performance of the Cytox genoBAR™ test with saliva samples.

 

The Cytox genoBAR research test is intended to help pharma, biotech, and sponsors of large cohort studies reduce the time and high cost associated with identifying and stratifying subjects for clinical trials and large-population research, which can take more than six months and run tens of thousands of dollars per participant. The work performed by Cytox and AKESOgen resulted in over 99% concordance between the SNPs used in the PRS identified from blood and saliva samples collected from the same subjects and run on the Cytox variaTECT™ microarray on the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform from Thermo Fisher Scientific. The saliva samples were collected using the DNA Genotek DNA saliva collection kit. The results of this verification study will provide an additional means to collect DNA from prospective clinical trial and cohort subjects and opens the possibility of screening even larger population groups for disease risk.

 

“The extension of our test to include saliva samples in addition to blood samples and biobanked DNA represents a significant step forward,” commented Dr Richard Pither, CEO of Cytox, “Our customers in pharma and biotech now have the ability to collect larger numbers of samples in a highly efficient and non-invasive way, opening the doors to the cost-effective screening of tens to hundreds of thousands of prospective clinical study participants, or still larger population networks associated with regional healthcare centres or national dementia programmes.”

 

Dr Mark Bouzyk, Chief Scientific Officer at AKESOgen, added, “The collaboration between AKESOgen and Cytox aims to ensure the highest accuracy possible across all the biological samples types generally used for genetic analysis. We believe these results and our partnership with Cytox will eventually result in more effective screening and diagnosis for those patients impacted by Alzheimer’s disease.”

 

-ends-

 

About Cytox

Cytox Group Limited is a precision medicine information company whose mission is to transform how treatments are developed, people are screened and therapies are prescribed for the most prevalent neurological diseases, including Alzheimer’s disease. Alzheimer’s disease today impacts over 46 million people globally, reaching 74.7 million in 2030 and projected to grow to over 131 million people by 2050 with an economic impact to exceed two trillion dollars. Leveraging the proprietary Cytox variaTECT™ SNP genotyping array, Cytox SNPfitR™ algorithm for polygenic risk scoring and running on the proven power and scalability of the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform, the company offers genomic profiling testing assays and services to early access collaborators in academia and Biopharma pursuing clinical research and drug development. The service is designed to help researchers and clinicians access the biology and genetics behind dementia, stratify patients to enable more cost effective and information rich clinical trials, and ultimately establish risk for cognitive decline and matching with the most appropriate targeted therapy.

 

The company is headquartered in the United Kingdom with assays and services available to early access collaborators globally. For more information, please visit www.cytoxgroup.com and follow the company on Twitter at @CytoxDx and on LinkedIn. Cytox’s assay and testing services are for research use only and not for use in diagnostic procedures.

 

About AKESOgen

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

 

 

Contact:

Cytox Limited

Richard Pither, CEO

+44(0) 1865 338018

richard.pither@cytoxgroup.com

www.cytoxgroup.com

 

AKESOgen

Mark Bouzyk, CSO

+1 770 542 0890

mbouzyk@akesogen.com

www.akesogen.com

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail

AKESOgen recognized as Georgia Small Business Rock Star of 2018

Georgia Economic Development Association

 

AKESOgen recognized as Georgia Small Business Rock Star

 

ATLANTA – March 19, 2018—AKESOgen was recognized by the state of Georgia as a Small Business Rock Star today at a luncheon hosted by the Georgia Department of Economic Development (GDEcD) and the Georgia Economic Developers Association (GEDA).

 

“What an honor it is to celebrate Georgia’s Small Business Rock Stars during the state’s annual Small Business Week,” said Commissioner Pat Wilson. “Anytime that we can put a spotlight on Georgia’s small businesses is a win-win for the state. These companies keep our economy thriving, and help Georgia maintain its status as the No.1 state in the nation in which to do business.”

 

Genetics and understanding your own genetic make up (DNA) is becoming pervasive in society. i.e. what makes you who you are. We are applying these new genetic technologies in fields such as cancer and Alzheimer’s as well as consumer genomics.” said Dr. Mark Bouzyk, Chief Scientific Officer at AKESOgen. “We are offering new precision medicine testing to understand outcomes and help identify which medicines make sense for the patient. In order for us to have grown this critical business we are deeply indebted to the outstanding support of GDEcD, Partnership Gwinnett, Georgia’s Innovation Crescent, the Georgia Research Alliance and GeorgiaBIO”.

 

This year’s Small Business Rock Stars winners include: AKESOgen, Inc. from Gwinnett County; STRAND Clinical Technologies from Columbia County; Gottwals Books from Peach County and SouthLife Supply Co. from Thomas County.

 

“With almost 98 percent of Georgia companies employing fewer than 100 people, small business has a tremendous impact on Georgia’s economy,” said GDEcD Director of Entrepreneur & Small Business Mary Ellen McClanahan. “The Rock Star recognition provides the perfect opportunity to showcase how important small businesses are to the state and of course, the local economy.”

 

These companies have shown increases in revenue, sales, exporting, product lines, jobs and economic impact. Additionally, the Small Business Rock Stars have shown dedication to their entrepreneurial spirit, creativity and a unique approach to conducting business to take them to the next level.

 

Governor Nathan Deal declared March 19-23 as Georgia Small Business Week to celebrate the achievements made my small businesses throughout the state.

 

“GEDA supports all types of economic development where jobs and investment are created, and where the quality of life is improved for our citizens,” said GEDA President Kevin Shea. “We are proud to support small businesses of all sizes through our members and their organizations all over the State of Georgia. Congratulations to this year’s award-winning small businesses.”

 

 

The Georgia Department of Economic Development’s small business efforts and outreach are directed by GDEcD Director of Entrepreneur & Small Business Mary Ellen McClanahan.  To access more information about these programs and more visit www.georgia.org/rockstars and www.georgia.org/smallbusinessweek.

 

###

 

About the Georgia Department of Economic Development

The Georgia Department of Economic Development (GDEcD) plans, manages and mobilizes state resources to attract new business investment to Georgia, drive the expansion of existing industry and small business, locate new markets for Georgia products, inspire tourists to visit Georgia and promote the state as a top destination for arts events and film, music and digital entertainment projects.

 

About GEDA

Celebrating 51 years of service excellence, the Georgia Economic Developers Association is the leading professional organization advancing Georgia’s economic vitality. GEDA is a non-profit association of professionals, volunteers and supporters. The association provides networking and professional development opportunities for its members, and supports public policies that promote quality job creation and sustainable economic development throughout the state. For more information, visit www.geda.org

 

About AKESOgen, Inc.

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and the College of American Pathologists (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail